Form 4: MAIA Biotechnology Director Stan Smith Acquires Shares and Warrants

Director Stan Smith purchased 170,940 shares of MAIA Biotechnology and corresponding warrants at $1.17 and $1.30 respectively, increasing his indirect holdings.

Summary

• On March 14, 2024, Stan Smith, a director of MAIA Biotechnology, acquired 170,940 shares of common stock at a price of $1.17 per share.
• The purchase was made under a Securities Purchase Agreement dated March 11, 2024, and the shares were issued under the company's 2021 Equity Incentive Plan.
• Smith also acquired warrants to purchase 170,940 shares of common stock at an exercise price of $1.30 per share.
• These warrants were also purchased under the Securities Purchase Agreement dated March 11, 2024, and are considered options issued under the 2021 Equity Incentive Plan.
• The warrants become exercisable six months from the issuance date (September 14, 2024) and expire five years after the initial exercise date (September 14, 2029).
• Following the transaction, Smith indirectly owns 857,568 shares through The Stan V. Smith Trust Dated 1993.
• Smith also indirectly owns 170,940 warrants through the same trust.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a standard transaction. The director's purchase is a positive signal, but it's not overwhelmingly significant.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This type of transaction is common in the biotechnology industry, where equity-based compensation and investments are frequently used to align the interests of management and shareholders.

Comparison to Industry Standards

• Comparing this transaction to similar insider purchases in comparable biotech companies would require analyzing the size of the purchase relative to Smith's existing holdings and the company's market capitalization.
• It would also be useful to compare the terms of the warrants (exercise price, expiration date) to those offered by other biotech companies.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholder sentiment.

Key Dates